u/endotoxin_ellie

log the cycle alongside the dose if you want the pattern to be visible

Are you tracking heart rate at all?

the hepatic data is what makes this compound different from the others

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

That figure is from the obesity programme, and this thread is about the hepatic one.

Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.

Why this board reports by lane and not by supplier.

Two members ordering from the same operation, in the same month, can see completely different transit times because they are on different routes with different carriers and different clearance points. Averaging them produces a supplier-level number that predicts nothing for either of them.

A lane — origin, destination, carrier, month — is the smallest thing that behaves consistently enough to be worth measuring. Once a route has a dozen reports behind it the median is genuinely useful, and that is what the tables on the source pages are built from.

Agreed — the template exists because a result without the batch and the claim is unanchored.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Which phase and which arm are you quoting?

valeria_karlsen is right about regional stock.

This is why the lane table is organised the way it is. The supplier is not the unit.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

ghost peak, check the plumbing first, it is always the plumbing

LC-MS for identity, UV for relative quantity

Right. And a blank between injections settles the carryover argument before it starts.

two labs, two gradients, two honest answers

Which paper is that claim from, and was it in humans?

Yes. Nothing here is approved for human use and that should be the first line of every thread, not the last.

Push back: the evidence here is phase 2, in a specific population, and it does not support a general ranking.

This. A quoted lead time that holds is worth more than a fast one that does not.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

This.

nordic_pricing is right about the escalation being the variable. It explains most of the difficult reports here.

Mass spectrometry answers identity.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

area percent unless the report says otherwise

piotr_nascimento is right that the band matters more than the peak. Consistency across lots is the finding.

A quoted lead time is a commitment you can evaluate.

chidi_demir is right about regional stock. It changes the shape of the distribution, not just the mean.

Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.

rigid outer packaging is the cheapest quality signal there is

Yes. Two services on the same batch is the strongest thing an individual member can produce, and it is not expensive.

regional stock changes everything about transit

Disagreeing with this bit: a single slow shipment does not move a lane, it joins the distribution.

Packaging is assessable on arrival with no equipment: rigid outer, no movement inside, the cold element sized to the transit rather than to the box.